Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11930.0
(-0.33%)
KRW 11930.0
(-0.33%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 29.77 Billion KRW | 24.47% |
| 2022 | 23.92 Billion KRW | -10.27% |
| 2021 | 26.65 Billion KRW | 13.99% |
| 2020 | 23.38 Billion KRW | 25.1% |
| 2019 | 18.69 Billion KRW | -13.11% |
| 2018 | 21.51 Billion KRW | -20.81% |
| 2017 | 27.17 Billion KRW | 65.71% |
| 2016 | 16.39 Billion KRW | -20.05% |
| 2015 | 20.5 Billion KRW | 9.06% |
| 2014 | 18.8 Billion KRW | 28.98% |
| 2013 | 14.58 Billion KRW | -7.7% |
| 2012 | 15.79 Billion KRW | 8.11% |
| 2011 | 14.61 Billion KRW | -15.23% |
| 2010 | 17.23 Billion KRW | 19.41% |
| 2009 | 14.43 Billion KRW | 29.41% |
| 2008 | 11.15 Billion KRW | -1.08% |
| 2007 | 11.27 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 4.51 Billion KRW | -27.27% |
| 2024 Q2 | 6.2 Billion KRW | -31.55% |
| 2024 Q1 | 9.07 Billion KRW | 19.88% |
| 2023 FY | 29.77 Billion KRW | 24.47% |
| 2023 Q1 | 7.11 Billion KRW | 35.29% |
| 2023 Q4 | 7.56 Billion KRW | 19.29% |
| 2023 Q3 | 6.34 Billion KRW | -27.46% |
| 2023 Q2 | 8.74 Billion KRW | 22.85% |
| 2022 Q2 | 5.57 Billion KRW | -33.1% |
| 2022 Q1 | 8.32 Billion KRW | 115.89% |
| 2022 Q4 | 5.26 Billion KRW | 10.52% |
| 2022 Q3 | 4.76 Billion KRW | -14.54% |
| 2022 FY | 23.92 Billion KRW | -10.27% |
| 2021 Q3 | 6 Billion KRW | -12.28% |
| 2021 FY | 26.65 Billion KRW | 13.99% |
| 2021 Q1 | 9.94 Billion KRW | 113.7% |
| 2021 Q2 | 6.84 Billion KRW | -31.13% |
| 2021 Q4 | 3.85 Billion KRW | -35.8% |
| 2020 Q3 | 7.44 Billion KRW | 53.51% |
| 2020 Q2 | 4.85 Billion KRW | -24.54% |
| 2020 FY | 23.38 Billion KRW | 25.1% |
| 2020 Q1 | 6.43 Billion KRW | 110.08% |
| 2020 Q4 | 4.65 Billion KRW | -37.53% |
| 2019 Q4 | 3.06 Billion KRW | -41.15% |
| 2019 Q2 | 2.79 Billion KRW | -63.37% |
| 2019 Q1 | 7.63 Billion KRW | 91.25% |
| 2019 FY | 18.69 Billion KRW | -13.11% |
| 2019 Q3 | 5.2 Billion KRW | 86.01% |
| 2018 Q1 | 5.71 Billion KRW | -11.33% |
| 2018 FY | 21.51 Billion KRW | -20.81% |
| 2018 Q4 | 3.99 Billion KRW | -28.02% |
| 2018 Q3 | 5.54 Billion KRW | -11.41% |
| 2018 Q2 | 6.26 Billion KRW | 9.5% |
| 2017 Q4 | 6.44 Billion KRW | 12.17% |
| 2017 FY | 27.17 Billion KRW | 65.71% |
| 2017 Q2 | 7.56 Billion KRW | 2.05% |
| 2017 Q1 | 7.41 Billion KRW | 297.78% |
| 2017 Q3 | 5.74 Billion KRW | -23.99% |
| 2016 Q4 | 1.86 Billion KRW | -62.85% |
| 2016 Q3 | 5.01 Billion KRW | 5.23% |
| 2016 Q2 | 4.76 Billion KRW | 0.24% |
| 2016 Q1 | 4.75 Billion KRW | 9.54% |
| 2016 FY | 16.39 Billion KRW | -20.05% |
| 2015 Q4 | 4.34 Billion KRW | -32.37% |
| 2015 FY | 20.5 Billion KRW | 9.06% |
| 2015 Q2 | 6.52 Billion KRW | 102.41% |
| 2015 Q3 | 6.41 Billion KRW | -1.67% |
| 2015 Q1 | 3.22 Billion KRW | -31.76% |
| 2014 Q3 | 4.56 Billion KRW | -9.42% |
| 2014 FY | 18.8 Billion KRW | 28.98% |
| 2014 Q4 | 4.72 Billion KRW | 3.53% |
| 2014 Q2 | 5.03 Billion KRW | 12.58% |
| 2014 Q1 | 4.47 Billion KRW | 6.97% |
| 2013 Q2 | 4.6 Billion KRW | 204.71% |
| 2013 Q1 | 1.51 Billion KRW | -65.31% |
| 2013 FY | 14.58 Billion KRW | -7.7% |
| 2013 Q4 | 4.18 Billion KRW | -2.14% |
| 2013 Q3 | 4.27 Billion KRW | -7.2% |
| 2012 Q1 | 3.41 Billion KRW | -1.23% |
| 2012 Q2 | 3.81 Billion KRW | 11.69% |
| 2012 Q3 | 4.21 Billion KRW | 10.53% |
| 2012 FY | 15.79 Billion KRW | 8.11% |
| 2012 Q4 | 4.35 Billion KRW | 3.47% |
| 2011 FY | 14.61 Billion KRW | -15.23% |
| 2011 Q2 | 2.25 Billion KRW | -50.55% |
| 2011 Q4 | 3.45 Billion KRW | -20.43% |
| 2011 Q1 | 4.56 Billion KRW | 43.45% |
| 2011 Q3 | 4.34 Billion KRW | 92.53% |
| 2010 Q2 | 5.17 Billion KRW | 30.19% |
| 2010 FY | 17.23 Billion KRW | 19.41% |
| 2010 Q4 | 3.17 Billion KRW | -35.27% |
| 2010 Q3 | 4.91 Billion KRW | -5.06% |
| 2010 Q1 | 3.97 Billion KRW | 16.05% |
| 2009 Q1 | 3.54 Billion KRW | 351.46% |
| 2009 FY | 14.43 Billion KRW | 29.41% |
| 2009 Q3 | 3.8 Billion KRW | 3.87% |
| 2009 Q2 | 3.66 Billion KRW | 3.13% |
| 2009 Q4 | 3.42 Billion KRW | -9.93% |
| 2008 FY | 11.15 Billion KRW | -1.08% |
| 2008 Q1 | 4.58 Billion KRW | 137.98% |
| 2008 Q2 | 3.2 Billion KRW | -30.04% |
| 2008 Q3 | 2.57 Billion KRW | -19.56% |
| 2008 Q4 | 786.07 Million KRW | -69.52% |
| 2007 Q4 | 1.92 Billion KRW | -46.34% |
| 2007 Q1 | 2.92 Billion KRW | 0.0% |
| 2007 Q2 | 2.83 Billion KRW | -3.32% |
| 2007 FY | 11.27 Billion KRW | 0.0% |
| 2007 Q3 | 3.58 Billion KRW | 26.75% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 514.632% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 48.656% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 149.968% |
| HANDOK Inc. | -28.79 Billion KRW | 203.392% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 453.817% |
| Yuhan Corporation | 93.5 Billion KRW | 68.159% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -167.695% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 220.0% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 79.639% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -748.608% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1287.925% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 1535.662% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 758.02% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -33.321% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 514.632% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 242.183% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -730.902% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 125.175% |
| JW Holdings Corporation | 19.02 Billion KRW | -56.49% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 137.723% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 85.99% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 19.543% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 151.939% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -386.369% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -1689.818% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -494.922% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 514.632% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 19.454% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 73.297% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 19.543% |
| Yuhan Corporation | 93.5 Billion KRW | 68.159% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 283.229% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 868.262% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -386.57% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 19.543% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -57.488% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 38.307% |
| CKD Bio Corp. | -24.19 Billion KRW | 223.072% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -24.491% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -8.514% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 151.939% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 36.66% |
| Boryung Corporation | 40.2 Billion KRW | 25.94% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 195.036% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1287.925% |
| JW Lifescience Corporation | 28.14 Billion KRW | -5.793% |